Avastin indicated for cervical cancer
Avastin (bevacizumab;Roche) is now licensed, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. This is in addition to its use in advanced non-small cell lung cancer or advanced cancers of the bowel, breast or kidney.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068293
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com